WallStreetZenWallStreetZen

NYSEMKT: CANF
Can Fite Biopharma Ltd Stock Ownership - Who owns Can Fite Biopharma?

Insider buying vs selling

Have Can Fite Biopharma Ltd insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when CANF insiders and whales buy or sell their stock.

CANF Shareholders

What type of owners hold Can Fite Biopharma Ltd stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Morgan Stanley0.00%33,007$77.24kInstitution
Rhumbline Advisers0.00%17,922$41.94kInstitution
Susquehanna International Group LLP0.00%12,047$28.19kInstitution
Fifth Third Bancorp0.00%3,000$7.02kInstitution
National Bank Of Canada0.00%600$1.40kInstitution
Citigroup Inc0.00%553$1.29kInstitution
Jpmorgan Chase Co0.00%460$1.08kInstitution
Td Waterhouse Canada Inc0.00%20$46.80Institution
Concourse Financial Group Securities Inc0.00%0$0.00Institution

1 of 1

CANF vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CANF0.01%0.00%
ALRN3.34%96.66%Net BuyingNet Buying
BCEL31.32%21.52%Net SellingNet Selling
TRVN4.05%95.95%Net SellingNet Selling
ATHE0.00%0.00%

Can Fite Biopharma Stock Ownership FAQ

Who owns Can Fite Biopharma?

Can Fite Biopharma (NYSEMKT: CANF) is owned by 0.01% institutional shareholders, 0.00% Can Fite Biopharma insiders, and 99.99% retail investors. Morgan Stanley is the largest individual Can Fite Biopharma shareholder, owning 33,007.00 shares representing 0.00% of the company. Morgan Stanley's Can Fite Biopharma shares are currently valued at $77.24k.

If you're new to stock investing, here's how to buy Can Fite Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.